Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
Did you know?
What made us buy IEX@193, Tata Power@56, Titan@330, Divis@629, Persistent@700.
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Zenotech Laboratories Ltd Stock Analysis

Small Cap
Evaluated by 167 users | BSE: 532039 | NSE: |
Pharmaceuticals & Drugs

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Capital Employed -24.2%-14.43%-48.86%-41.81%-66.43%-77.14%932.88%-66.66%-5.85%10.9%-0.19%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 72.232.84.12.12.311.1132622.527
Y-o-Y Gr. Rt.--68.9%39.5%-9.2%47.8%-49.5%9.2%395.1%17%99.7%-13.7%-
Adjusted EPS (Rs.) -5.99-2.53-6.97-6.24-8.36-5.21-5.83-1.94-0.51.04-0.20.93
Y-o-Y Gr. Rt.-NANANANANANANANANA-119.2%-
Book Value per Share (Rs.) 17.0614.237.20.9-7.51-12.7-18.176.886.378.137.938.66
Adjusted Net Profit -21.7-9.2-25.3-22.6-30.3-18.9-21.1-11.8-36.3-1.26
Net Op. Cash Flow (Rs. Cr.) 0.8-1.7-9.8-24.3-7.7-4.81.6-16.3-1411.45.7-
Debt to Cash Flow from Ops 4.39-3.07-1.65-1.93-7.04-11.3133.160-1.441.643.6-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Zenotech Laboratories Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales 29.6%61.2%26.3%-13.7%
Adjusted EPS NANANA-119.2%
Book Value per Share -6.304.9-2.5
Share Price 2.2% 3.3% 5.2% 48.8%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Equity (%) -26.87-16.14-65-154.01252.7851.5537.7499.15-7.5114.27-2.4811.21
Operating Profit Margin (%) -161.76-220.87-667.61-616.98-488.24-372.5-460.42-70.49-26.0434.5128.4247.32
Net Profit Margin (%) -310.13-419.4-830.18-820.89-743.61-917.4-937.42-106.26-23.3324.28-5.4120.78
Debt to Equity 0.050.10.6214.44-1.99-1.18-0.8200.520.380.430.23
Working Capital Days 46484966783254384261014823912511184
Cash Conversion Cycle 994089297186252106-70-42-44-9-
Loading price chart...
Entity Percentage Holding
Promoters 68.84%
Institutions 0.01%
Non-Institutions 31.15%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Zenotech Laboratories Ltd's earnings have grown by 0%, whereas share price has appreciated 3.3% CAGR over the past five years, indicating the company’s share price is likely overvalued. However, for specific investment actions please consult your investment advisor.

Zenotech Laboratories Ltd share price has appreciated 2.2% annually (CAGR) over the past ten years.

Data is not available for this company.

Zenotech Laboratories Ltd, formerly known as Sunline Technologies Limited, was originally incorporated as Maa Shakti Tube Mill private Limited on June 15,1989. Zenotech develops and manufactures generic biopharmaceuticals and markets them to people with unmet medical needs around the world.

The company aims to bring a constant pipeline of new biogeneric products to the market. The highly qualified and trained staff uses recombinant DNA technology and cGMP

Zenotech Laboratories Ltd, formerly known as Sunline Technologies Limited, was originally incorporated as Maa Shakti Tube Mill private Limited on June 15,1989. Zenotech develops and manufactures generic biopharmaceuticals and markets them to people with unmet medical needs around the world.

The company aims to bring a constant pipeline of new biogeneric products to the market. The highly qualified and trained staff uses recombinant DNA technology and cGMP production methods to give the customers generic versions of biotherapeutic drugs comparable to the innovator product in quality, safety and efficacy.

Zenotech’s technical staff are well versed in gene cloning and expression, fermentation, downstream processing, protein purification, process validation and manufacture of recombinant DNA products from bacterial, yeast and mammalian cells.

Zenotech has a full fledged research and development facility for generating recombinant proteins for clinical development. The company plans to set up cGMP manufacturing facilities that will house multiple fermentors, bioreactors and chromatography systems to meet the demands of the Indian and other emerging markets.

Zenotech develops new biological entities in the areas of cancer and neurology. The company has initiated target identification and validation programs using gene and protein based technologies. This brings together proprietary technologies in the identification of cell surface proteins and receptors as candidate drug targets.

Zenotech utilizes validated targets for generating new therapeutic entites. The company plans to adopt a comprehensive approach to therapeutic monoclonal antibody generation by bringing together skills in the areas of recombinant DNA technology, protein purification and characterization in the development of new antigen and antibody-based therapeutics for clinical studies.

Zenotech offers comprehensive services for generating and characterizing recombinant proteins. The company provides a full range of services from cloning a gene, expression in microbial or mammalian systems, process development and generation of milligram to gram quantities of pure recombinant proteins. The company also offers functional, validated assays in both cell-based and cell-free formats for use in drug discovery.

Product range of the company includes:

Generics -- Biological

  • Nugraf
  • Macrogen

        Chemical

  • Gemcitabine for Injection 
  • Paclitaxel for Injection 
  • Docetaxel for Injection 
  • Irinotecan for Injection 
  • Oxaliplatin for Injection 
  • Epirubicin for Injection 
  • Bleomycin for Injection 
  • Cisplatin for Injection 
  • Carboplatin for Injection 
  • Ifosfamide for Injection 
  • Etoposide for Injection

New biologicals Zenotech develops new biological entities in the areas of

  • Cancer
  • Neurology
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback